top of page

Press Release - 5/4/20

Halomine™ Announces CTAM Support for Regulatory Work

MAY 4, 2020

(Ithaca, NY) — Halomine™ today announced that it has received an investment from The Cornell Technology Acceleration Maturation (CTAM) Fund to assist the company to achieve regulatory approval for its breakthrough product HaloFim™. The investment is designed to finance retention of counsel to guide the company through the regulatory approval process and any necessary testing in anticipation of its product launch later this year.


HaloFilm™ is a revolutionary new product that can hold germ-killing chlorine cleaning products on a treated surface for days. It is a spray-on, re-applicable antimicrobial coating that enables recommended disinfecting products to remain effective for weeks instead or minutes.

“Halomine is gratified that CTAM has provided this important capital. The data are clear: HaloFilm™ binds with chlorine molecules to hold the chlorine in place and provides around-the-clock chlorine antimicrobial protection in a safe and effective manner that does not damage surfaces or irritate skin. This money will allow the company to address its regulatory requirements quickly and effectively,” said Halomine CEO Ted Eveleth. 

Halomine Inc. is a startup company based on a Cornell discovery and founded by Dr. Mingyu Qiao. Dr. Qiao, Halomine’s CTO, is a former postdoctoral associate whose research in the Department of Biological and Environmental Engineering at the Cornell College of Agriculture and Life Sciences, focused on the synthetic compound known as N-halamine and its real-world applications.  Ted Eveleth recently joined as Halomine Inc.’s CEO. Mr. Eveleth, who has guided a number of start-ups through early development, received his MBA from the Cornell SC Johnson College of Business in 1990. 
The Cornell Technology Acceleration Maturation Fund is a resource available to the Cornell research community and is managed by the Center for Technology Licensing at Cornell University.  The objective of the CTAM Fund is to provide critical funding to advance promising technologies towards key inflection points for commercialization and venture creation.

Halomine Inc. was awarded CTAM funding as part of the Fall 2019 program cycle. Halomine’s proposal, entitled “Novel Self-sanitizing Coating for Mitigating Health-care Associated Infections Acquired from Hospital Hand-touch Surfaces,” focused on funding regulatory activities to move the company closer towards commercialization. 

Halomine’s proposal stood out among a record-high number of high-quality applications.  Eveleth, Qiao and the Halomine Inc. team are working to complete their project in 2020. 

HaloFilm™ is a “chlorine-extender,” which means after spraying HaloFilm™ on a surface, it binds with and traps the chlorine in place. Each time germs touch the treated surface, HaloFilm™ releases enough chlorine to kill the germs on the surface, but it continues hold the rest of the chlorine in place. HaloFilm™ allows the bound chlorine to provide germ-killing protection for days. 

About Cornell Technology Acceleration and Maturation (CTAM) Fund

Cornell University provides numerous resources to help technology commercialization and new venture formation. One such resource is the Cornell Technology Acceleration and Maturation (CTAM) Fund. The objective of the CTAM Fund is to provide critical funding to advance promising technologies towards key inflection points for commercialization and venture creation 


About CTL 







The Center for Technology Licensing (CTL) is Cornell University’s technology transfer office. We manage technology for Cornell’s Ithaca campus, Weill Cornell Medicine (WCM), Cornell Tech, and Cornell AgriTech in Geneva. CTL’s mission is to bring the University’s scientific discoveries, technological innovations, and medical advances to the marketplace for societal benefit and to foster economic development within New York State and across the nation. 


A Rechargeable Antimicrobial Technology 

Mingyu Qiao, Ph.D., came to Cornell to study with Professor Minglin Ma and to launch a new rechargeable antimicrobial technology—a void in the healthcare industry.


Have a question, comment, or inquiry for the Halomine team? We would love to answer them. Simply fill out the form below and a Halomine representative will be in touch shortly.

Thanks for submitting!

Contact Halomine

bottom of page